Generated by AI
Werewolf Therapeutics Inc. is a biopharmaceutical company focused on developing conditionally activated therapeutics designed to stimulate the immune system for the treatment of cancer and other immune-mediated conditions. The company’s current work centers on its proprietary PREDATOR platform, which is used to create INDUKINE and INDUCER molecules intended to activate selectively in diseased tissue while limiting activity in healthy tissue. Its pipeline includes immune-modulating candidates aimed at solid tumors and specific cancer targets, reflecting a concentration on oncology and immunotherapy. Werewolf Therapeutics Inc. operates as a clinical-stage developer of advanced biologic therapies, with research and development activities spanning tumor-directed immune activation and targeted protein engineering. Headquartered in Watertown, Massachusetts, the company is positioned within the biotechnology sector as a specialist in next-generation cancer therapeutics.
Website200 Talcott Ave
Watertown, MA, 02472
United States
The latest articles about HOWL.
Detailed price information for Werewolf Therapeutics Inc (HOWL-Q) from The Globe and Mail including charting and trades.
Summary of Aug 26's posts. Generated by AI.
Summary of Aug 24's posts. Generated by AI.
Summary of May 25's posts. Generated by AI.
Summary of Aug 26's posts. Generated by AI.
Investors talking about HOWL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.